Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting

NCT02717962 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

118

Enrollment

INDUSTRY

Sponsor class

Conditions

Glioma
Glioblastoma
Glioblastoma Multiforme
GBM
Brain Cancer

Interventions

DRUG: VAL-083, Dianhydrogalactitol

Sponsor

Kintara Therapeutics, Inc.